INDIAN PHARMACEUTICAL

INDUSTRY

AN OVERVIEW

INDIA IS RANKED 15TH IN TERMS OF VALUE IN THE GLOBAL PHARMA MARKET HIGH POPULATION GROWING ROBUST ECONOMY SLATES INDIA AS A KEY PLAYER ON THE GLOBAL SCENE BENCHMERKS: ACCEPTANCE OF PRODUCT PATENTS IN 2005 INDIA HAS THE SECOND HIGHEST FDA MANUFACTURING UNITS, SECOND ONLY TO USA PAVES WAY TO INCREASED RESEARCH & INNOVATION LAUNCH OF NEW PATENTED PRODUCTS LEADS TO FURTHER GROWTH

GROWTH MATRIX

PERFORMANCE MATRIX
multiply by 4.5 for fig in mil$

multiply by 4.5 for fig in mil$

multiply by 4.5 for fig in mil$

THE GUIDING STARS

TO SUMMARISE..
Indian Pharma Market has bounced back in 06. Both acute & chronic therapies have witnessed double digit growth. The indicators point towards robust growth in all the areas Pharma companies are laying down their own success path with focus on their core competence Companies accordingly bank on different business models like portfolio diversification price premium price cuts regional penetration therapy focus encash brand equity And the success has been achieved by setting their own benchmarks and trying to raise their performance bars themselves.

This representation of the Indian Pharmaceutical Industry

reveals that..
Indian Pharma Companies adopt and implement various long term and short term strategies, however the strategy that leads the peak of success, is the right strategy. Apart from the predictable marketing and sales efforts of companies, many times it is uncontrolled market dynamics, intuition and likeability that drive the result of these efforts. The perfect combination of all these through all the environmental highs and lows wades the path for an INDIAN PHARMACEUTICAL INDUCTRY to become successful benchmark

IT ALSO REVEALS THAT THERE IS AN IMMENSE TIE UP (TRADE) OPPORTUNITY WITH INDIAN PHARMACEUTICAL INDUSTRY.
In fact we as an industry are already at the various stages of discussions for strategic alliances with various companies at global level.

Specifically for Hong Kong it serves as our South East Asia touch Point, it could also serve as an ideal Corporate base for the organizations.
China is for the Pharma industry a sourcing point, and in near future will become much more than just a bulk supplier due to the simple fact that nobody wants one time business partner, the industry everywhere is looking for long haul, a rapport for a long term relations.

As a generalized conclusion:
We foresee a highest ever growth in the India-China trade in the Pharmaceutical sector for next 5 years.
In fact to be precise, us Indians & Chinese as far as our sector is concerned,

We as an industry became very interdependent on each other very fast, and maybe at the corporate level the action is starting now.#
Again we see the competitive edge but not so much clash of interests if we stick to our core competencies

MANEESH PHARMACEUTICALS

SVIZERA

SVIZERA EUROPE
SVIZERA HEALTHCARE MANEESH HEALTHCARE

PHARMATECH

SVIZERA LABS

Bombay BioResearch Centre

AN ISO 9001:2000 COMPANY Certificate GB03/58497 Certified with SGS UK

CRISIL - India's most influential opinion & solutions company on risk & policy has rated Maneesh Pharmaceuticals as ' SME 1' ranking. The highest rating on risk-worthiness

Advancing medicine sustaining healthcare

Maneesh Pharmaceuticals has emerged as a integrated Pharma company with capabilities from Research to Global marketing of Branded Generics and NDDS.

IT is one of the very few companies, which offer specialized facilities dedicated to the same therapeutic group of products. Anti-infectives (Anti-TB, Anti-malarial, Anti HIV-AIDS) Antibiotics Hormones Oral Contraceptive Pills Soft-Gelatine Casules Dermatology (Ointments & Creams) And Other

MANEESH PHAMACEUTICALS

Registered Office: 24-24, Kalpataru Court, Dr. C. G. Marg, Chembur, Mumbai- 400 074 Tel No. +91-22-2525 2122/23/24 Fax No. +91-22-2525 2121 E-mail: info@maneeshpharma.com

VISIT US AT: www.maneeshpharma.com

Success Track
World class manufacturing facilities

Exports to over 70 countries

Dedicated units for Anti-TB drugs & Hormones

Expanded domestic market operations

Scouting strategic opportunities off shore

Set up R&D Center /Clinical Research Center

R&D Center

A Global Quality CRO

2006-

CRO Started. A State of Art Clinical Research Organisation started functioning. Already contracted 22 studies form other organisations besides our own studies. Will help to provide good support in our efforts for registration of products in Regulated Markets of USA and Europe
20062006-

R & D Centre is being set up to accelerate the filing of Registrations in USA and EUROPE. Invested USD 6.0 million in SYNOVICS, USA a research based listed company. To facilitate ANDA filings and to ensure supply arrangements.
20062006-

New USFDA compliant facility planned to be utilised for the above venture. MOU signed with Kirk Pharma, USA for supplies of Products. A new Plant for Soft Gelatine capsules in constructed for this purpose. Expected to start functioning from Dec. 2006
2006-

Svizera SA (pty) a set up as a base in South Africa to tap South African regulatory market

What next?

Future Strategy:
To expand our operations in USA and Europe In USA with the Help of Synovics we are on the verge of starting distribution. We have acquired a company in Europe with existing Registrations and approvals. This will be used as an base to enter European Markets. We also have plans in progress to acquire a medium sized distributor in UK or Europe. To expand the Indian operations by adding more products in New Therapeutic segments mainly the chronic segment like diabetes and hypertension. And increasing the reach to cover more doctor populations. (Today we cover approx. 23%). We already have products developed for reaching the same. To further expand Globally by entering other markets Like Russia, south east Asia and CHINA with own product registrations. To further expand in Latin America using BRAZIL as a base To do Backward Integration by manufacturing key APIs required for Own consumption.

The expectations?

Standardization of policy, International & domestic

Pricing Quality Scientific Regulatory Guidelines Therapeutic Guidelines Legal Patents Trademark

An integrated collective body for governance in the industry

Transparency

in operations at all levels

Future
India from pharmaceuticals industry view point: I see India as a hub for deliverance whatever is in demand I also see India as an already emerged Industry, on the brink of another revolution in the happening, Not only as manufacturer or a labour offering land but as a global finished goods maker adhering to the quality dynamics I also see Indian industry further evolving as leader, having a upper hand dealing with lots of synergistic acquisitions. The largest ever opportunity I see for my industry in my country is for the Brands & Quality Generics both going hand in hand, playing a key role in making drugs available, accessible & affordable Besides a new generation of emerging speciality & super speciality professionals And the industry growing further by looking at big boom expected, currently on the verge of sprouting of

HEALTHCARE TOURISM

Our aim is to become a Globally competitive Integrated Pharma solution with capabilities from R & D to Global Marketing. Thank You